Printer Friendly

Research groups eyes up clinical trials.

Birmingham medical research group Henderson Morley has started new clinical trials of Ionic Contra Viral Therapy (ICVT), a treatment for a particular type of conjunctivitis.

The study will examine the safety of ICVT when used to treat Adenovirus Keratoconjunctivitis. Henderson yesterdaysaid it was informed by its development partner Croma Pharma that all six trial centres in Austria and Slovakia had received the necessary ethics committee approval and that stocks of the treatment had been delivered.

Treatment of the first patients, who were enrolled during January, has now started.

Dr Andreas Clausen, head of the clinical project team for the ICVTA12 trial, said: 'The start of this clinical trial means that our aim of producing a safe and effective therapy for Adenoviral Keratoconjunctivitis has taken a step forward.'
COPYRIGHT 2004 Birmingham Post & Mail Ltd
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Business
Publication:The Birmingham Post (England)
Date:Feb 10, 2004
Words:127
Previous Article:Record land deals for property consultancy.
Next Article:Cerro's press first in the UK; Italian engineering: Technology key to cost-effective production.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters